Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Telomir Pharmaceuticals, Inc. - Common Stock
(NQ:
TELO
)
0.9352
-0.0290 (-3.01%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Telomir Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
January 28, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Findings for Age-Reversal Therapy
January 07, 2025
Via
Investor Brand Network
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
January 07, 2025
Via
ACCESSWIRE
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Advances Copper-Binding Drug for Wilson’s Disease and Age-Related Therapies
December 23, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
August 20, 2024
Via
ACCESSWIRE
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
December 23, 2024
Via
ACCESSWIRE
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease
↗
December 23, 2024
Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation.
Via
Benzinga
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
December 17, 2024
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Via
News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies
December 12, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
December 12, 2024
Via
ACCESSWIRE
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
↗
December 03, 2024
Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases.
Via
Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Preclinical Results in Type 2 Diabetes Treatment
December 03, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
December 03, 2024
Via
ACCESSWIRE
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study
November 22, 2024
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study
Via
News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal Science
November 21, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
November 21, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”
September 27, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
September 26, 2024
Via
ACCESSWIRE
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
September 05, 2024
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
Via
News Direct
BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor
September 04, 2024
Via
Investor Brand Network
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
September 04, 2024
Via
ACCESSWIRE
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
August 19, 2024
Via
Benzinga
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024
↗
August 13, 2024
Telomir Pharmaceuticals just reported results for the second quarter of 2024.
Via
InvestorPlace
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging
May 31, 2024
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging
Via
News Direct
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024
↗
May 13, 2024
Telomir Pharmaceuticals just reported results for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
April 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
April 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
March 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 12, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
